Simplify Logo

Full-Time

Senior Scientist

Computational Biology

Posted on 6/18/2024

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$160k - $200kAnnually

Senior, Expert

Cambridge, MA, USA + 1 more

More locations: San Bruno, CA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Python
Git
Requirements
  • PhD in computational biology, bioinformatics, genetics, or related discipline with up to 5+ years of industry experience (or MSc with 7+ years of industry experience)
  • Strong scientific background including an understanding of molecular biology and genomics
  • Familiarity with NGS platforms and hands-on experience with all steps for analyzing NGS data
  • Demonstrated proficiency in script languages such as Python and familiarity with a compiled language such as C/C++ or Java
  • Routine use of version control such as git
  • Experience with high performance computing
  • Demonstrated strong analytical skills and problem-solving
  • Be detail oriented, self-motivated and able to prioritize multiple projects concurrently
Responsibilities
  • Develop and optimize analysis workflows to analyze NGS data, including both whole genome sequencing (WGS/WES), targeted sequencing, and bulk/single cell RNA Seq
  • Develop novel Bioinformatics methods to answer platform and biological questions, and demonstrate validity of methods through prototypes and benchmarking using appropriate controls
  • Work with other computational biologists and computational engineers to deliver and optimize production-level pipelines
  • Proper documentation of code, workflows, and analyses including study reports for nonclinical and clinical studies and regulatory filings
  • Communicate to a broad audience with a range of technical, analytical, and biological expertise and present results on a regular basis at various group meetings

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases by addressing their root causes. Their approach involves repairing and controlling genes within cells or replacing damaged or missing cells, which can lead to new types of medicines that improve patient outcomes. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. Unlike many competitors, Sana focuses heavily on research and development of cellular therapies, monetizing their innovations through licensing agreements and partnerships. Their goal is to create effective treatments for a wide range of diseases, enhancing patient care and outcomes.

Company Stage

IPO

Total Funding

$865M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

1%

1 year growth

-11%

2 year growth

-27%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sana's recent FDA clearance for investigational new drug applications, such as SC262 and SC291, indicates promising progress in their clinical trials.
  • The company's ability to raise significant funds through PIPE offerings and public stock offerings demonstrates strong investor confidence and financial stability.
  • Expansion into key biotech hubs like Cambridge, MA, suggests growth opportunities and access to top-tier talent.

What critics are saying

  • The resignation of key executives like Dr. Douglas Williams could disrupt R&D momentum and strategic direction.
  • High competition in the biotechnology sector, especially in gene and cell therapy, may impact market share and revenue growth.

What makes Sana Biotechnology unique

  • Sana Biotechnology focuses on engineered cells to treat and potentially cure diseases at their genetic and cellular roots, setting it apart from traditional pharmaceutical approaches.
  • Their heavy investment in R&D and partnerships with pharmaceutical companies and research institutions provide a robust pipeline for innovative therapies.
  • Sana's hypoimmune platform, which aims to create cells that can 'hide' from the patient's immune system, is a unique technological advancement in the field.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE